![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FCRL5 |
Gene summary for FCRL5 |
![]() |
Gene information | Species | Human | Gene symbol | FCRL5 | Gene ID | 83416 |
Gene name | Fc receptor like 5 | |
Gene Alias | BXMAS1 | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q96RD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83416 | FCRL5 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.52e-09 | 8.28e-01 | 0.1479 |
83416 | FCRL5 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 2.22e-03 | 5.26e-01 | 0.1531 |
83416 | FCRL5 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.50e-02 | 4.14e-01 | 0.1619 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FCRL5 | SNV | Missense_Mutation | c.2188G>T | p.Asp730Tyr | p.D730Y | Q96RD9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FCRL5 | SNV | Missense_Mutation | c.1456G>A | p.Glu486Lys | p.E486K | Q96RD9 | protein_coding | tolerated(0.15) | possibly_damaging(0.761) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FCRL5 | SNV | Missense_Mutation | novel | c.1585N>A | p.Phe529Ile | p.F529I | Q96RD9 | protein_coding | deleterious(0.05) | benign(0.118) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
FCRL5 | SNV | Missense_Mutation | novel | c.1963C>T | p.Pro655Ser | p.P655S | Q96RD9 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FCRL5 | SNV | Missense_Mutation | c.1096A>T | p.Ser366Cys | p.S366C | Q96RD9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FCRL5 | SNV | Missense_Mutation | c.2106N>T | p.Lys702Asn | p.K702N | Q96RD9 | protein_coding | tolerated(0.7) | benign(0.006) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FCRL5 | SNV | Missense_Mutation | c.1079N>A | p.Gly360Asp | p.G360D | Q96RD9 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
FCRL5 | SNV | Missense_Mutation | c.297N>A | p.Asp99Glu | p.D99E | Q96RD9 | protein_coding | tolerated(0.38) | benign(0.012) | TCGA-AR-A0TR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
FCRL5 | SNV | Missense_Mutation | novel | c.2593G>A | p.Gly865Arg | p.G865R | Q96RD9 | protein_coding | deleterious(0.02) | possibly_damaging(0.614) | TCGA-AR-A5QN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
FCRL5 | SNV | Missense_Mutation | c.142C>T | p.Arg48Cys | p.R48C | Q96RD9 | protein_coding | tolerated(0.06) | benign(0.067) | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |